| Biological Information | |
|---|---|
| Background Information: | Transforming growth factor, beta receptor type I (TGF-beta receptor I) forms a heteromeric complex with TGF-beta receptor type II when bound to TGF-beta. This complex transduces the TGF-beta signal from the cell surface to the cytoplasm. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. TGF-beta receptor I is found in all tissues, but is most abundant in placenta and least abundant in brain and heart tissue. TGF-beta receptor I is phosphorylated at basal levels in the absence of ligand binding and is multiply phosphorylated, mainly in the GS region. Defects in TGF-beta receptor I are the cause of Loeys-Dietz syndrome type 1A (LDS1A), also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). |
| Target Class: | Kinase |
| Accession Number: | NM_004612 |
| Target Name: | TGFBR1 |
| Target Aliases: | TGFBR1 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
TGFBR-1, active
10 µg of active TGFBR-1. N-terminal GST-tagged recombinant, human TGFBR1 amino acids 200–end containing a T204D mutation.
Datasheets
14-912x Datasheet
View Document